Loading live market data…

Spyre Therapeutics, Inc.

NASDAQ:SYRE

$100.194 USD

$1.24 (1.26%)

Volume
284.63K
Average Volume
1.42M
Market Capitalization
$6.05B
P/E Ratio
-45.96
Dividend Yield
0.00%
Price Target
$100.00
Year High
$105.09
Year Low
$14.51
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$8.97

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Cameron Turtle
Industry Biotechnology
Sector Healthcare
Current Symbol SYRE
CUSIP 00773J202
CIK 0001636282
Web https://www.spyre.com
Phone 617 651 5940
Currency USD
Employees 112
Country US

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 8.97
Quick Ratio 8.97
Cash Ratio 1.14

Sales & Book Value

Annual Sales $-
Price / Sales 66.88
Cash Flow -0.54
Price / Cash Flow -32.57
Price / Book 51.69

Price Target and Rating

Average Stock Price Forecast $100.00
High Stock Price Forecast $135.00
Low Stock Price Forecast $49.00
Forecast Upside/Downside 0.19%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 12 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-1.98
Trailing P/E Ratio -45.96
PEG Ratio 0.91
P/E Growth 0.91
Net Income $-155.2M
Net Margin -198.28%
Pretax Margin -198.28%
Return on Equity -31.25%
Return on Assets -23.49%

Financials Score

AltmanZ Score 34.62
Piotroski Score 2.00
Working Capital 678.79M
Total Assets 763.95M
Ebit -194.65M
Market Cap 5.66B
Total Liabilities 93.14M

Poll Results

About Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs ... are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.

Spyre Therapeutics Announces Grants of Inducement Awards

2026-07-02 16:05:00

WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 58,843 shares of common stock of Spyre and 2,134 restricted stock units (“RSUs”) to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on July 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data

2026-06-30 08:00:00

Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However, they only have Phase 2 assets, with SPY001 and SPY002 that recently showed encouraging Part A data. We still need to wait to see their placebo-controlled data, as well as their combo therapy data.

Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today

2026-06-29 12:25:26

Spyre Therapeutics  SYRE has given investors a classic biotech dilemma. The pipeline is advancing, the cash balance is large and the stock has already moved sharply higher.

Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts

2026-06-29 12:21:15

Spyre Therapeutics  SYRE has become a closely watched clinical-stage biotech stock as investors look ahead to a busy stretch of data readouts that could define the company's next phase. The company is focused on inflammatory bowel disease, or IBD, where it is developing long-acting antibodies and antibody combinations aimed at improving disease control, convenience and durability of response.

SYRE and Spyre Ride New IBD Trends in Biotech Drug Design

2026-06-29 12:21:13

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.

Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset

2026-06-26 14:34:39

Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally developed, long-acting antibody combinations. Positive Phase 2 data for SPY001 and SPY002 in ulcerative colitis validate SYRE's approach, with a third monotherapy readout and multiple rheumatology catalysts expected in 2026. SYRE's $1.18B cash position funds operations into 2H 2029, supporting robust clinical execution and mitigating near-term dilution risk.

Biotech ETF Index Surges 10% After Rebalance

2026-06-25 11:31:47

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

Spyre says bowel disease drug cuts inflammation in mid-stage trial

2026-06-15 08:28:57

Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly ​reducing disease severity in a mid-stage trial.

Frequently Asked Questions

What is the current Spyre Therapeutics, Inc. (SYRE) stock price?

Spyre Therapeutics, Inc.(NASDAQ:SYRE) stock price is $100.194 in the last trading session. During the trading session, SYRE stock reached the peak price of $105.09 while $14.505 was the lowest point it dropped to. The percentage change in SYRE stock occurred in the recent session was 1.26% while the dollar amount for the price change in SYRE stock was $1.24.

SYRE's industry and sector of operation?

The NASDAQ listed SYRE is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of SYRE?

James Paul Kastenmayer | Consultant
Scott L. Burrows | Chief Financial Officer
Joshua Friedman | Senior Vice President of Clinical Development
Eric McIntyre | Senior Vice President of Finance & Investor Relations
James Myers | Senior Vice President of Quality & Compliance

How many employees does SYRE have?

Number of SYRE employees currently stands at 112. SYRE operates from 221 Crescent Street, Waltham, MA 02453, US.

Link for SYRE official website?

Official Website of SYRE is: https://www.spyre.com

How do I contact SYRE?

SYRE could be contacted at phone #617 651 5940 and can also be accessed through its website. SYRE operates from 221 Crescent Street, Waltham, MA 02453, US.

How many shares of SYRE are traded daily?

The average number of SYRE shares traded daily for last 3 months was 1.42M.

What is the market cap of SYRE currently?

The market value of SYRE currently stands at $6.05B with its latest stock price at $100.194